

IMPORTANT: This letter requires your immediate attention. If you have any questions about the content of this letter, you should contact your J.P. Morgan Asset Management representative or seek independent professional advice.

1st October 2025

Dear Investor,

**Change to primary listing venue –
JPMorgan Emerging Markets Research Enhanced Index Equity Active ETF (the “Fund”)
(TICKER: JREM)**

We, JPMorgan Asset Management (Australia) Limited, the manager of the Fund (“**Manager**”) would like to announce that the Fund has sought to obtain admission as an AQUA product listed on the ASX as its primary listing venue. Consequently, we are targeting de-quotation from Cboe on or around 31st October 2025 (“**Cboe De-quotation Date**”), and a subsequent commencement of trading on ASX is expected to be on or around 3rd November 2025 (“**ASX Listing Date**”). Should there be any changes to these dates, we will keep investors updated.

The responsible entity of the Fund is Perpetual Trust Services Limited ABN 48 000 142 049, AFSL 236648 (“**Responsible Entity**”).

As a result of this change, there will be a trading halt from 29th to 31st October 2025. Trading will resume on the ASX Listing Date, under a new ticker “**JEME**”.

As an investor, no action is required. You may continue to buy and sell units of the Fund on and from the ASX Listing Date.

Key dates

Date	Event
1 st October 2025	Notice to investors
21 st October 2025	Application for De-quotation from Cboe
28 th October 2025	The last trading day on Cboe under ticker JREM
29 th to 31 st October 2025	Trading halt
31 st October 2025	De-quotation Day on Cboe under ticker JREM
3 rd November 2025	ASX Listing Date - the Fund will be available for trading on ASX and Cboe under a new ticker “ JEME ”

Impact to you

The change in primary listing venue does not affect the way you trade units of the Fund, nor the number of units you hold. We do not anticipate any impact to the distribution payout date during this period.

On the ASX Listing Date, the Fund will be available for trading on both ASX and Cboe with the new ticker “**JEME**”. As an investor, there is no difference in the manner in which you will buy or sell the Fund’s units. The decision on which exchange to trade is usually made by your participating broker.

The information provided in this notice is for general information only and does not take into account your objectives, financial situation, tax position or needs. You should read the PDS and seek independent financial and tax advice tailored to your personal circumstances. Subject to obtaining all relevant approvals, a replacement PDS will be issued as of the ASX Listing Date by the Responsible Entity. A copy of the PDS and Target Market Determination will be available at www.jpmorganam.com.au or upon request at the registered office of the Manager. A copy of the Fund’s Constitution is available at no charge from the Responsible Entity on request.

If you have any questions with regard to the contents of this letter, please do not hesitate to contact us on 1800 576 468.

Yours faithfully,



Mark Carlile
Head of Wholesale
JPMorgan Asset Management (Australia) Limited